BEXSERO® non-live (recombinant) meningococcal group B vaccine



2 months[¥] to 25 years **DIN 02417030**



YC

SUPPLIED: prefilled syringe:

prefilled syringe; needle may not be supplied



PREPARATION: ready-to-use; DO NOT DILUTE



ADMINISTRATION: IM injection

	APPROPRIATE USE:	 May be publicly funded in SK See QR code for recommendations for use. Off-label Use: may be considered for ≥ 26 years* 	
Č,	BEYOND-USE EXPIRY DATE/TIME:	 Check date on label (expiry date) 2°C and 8°C: use vaccine until expiry date. 	
	HANDLING:	SHAKE WELL before administration to re-susper	nd.
	APPEARANCE:	White opalescent liquid suspensionNO foreign particulate matter/discolouration	
milt	DOSE:	• 0.5 mL	
Ī	SERIES/SCHEDULE:	 PRIMARY SERIES: 2-dose: 0, ≥ 1 month BOOSTER: May be considered for individuals at co See PM for details . 	ntinued risk.
* Pharmae * as per t		hose 5 years and older.	
ne(Sask NINFORMATION SERVICE	BEXSERO® product monograph Saskatchewan Immunization Manual Chapter 10 Canadian Immunization Guide: Meningococcal Vaccines CATMAT Statement on Meningococcal Disease and the International Traveller	Financial contribution: Public Health Agency of Canada Publique du Canada 25 MAR 2024 ©2024 medSask // Townes & Park Designs